PRMT6 and osteoporosis: Importantly, our studies show that PRMT6 inhibition does not adversely affect osteogenic differentiation in vitro, as evidenced by unchanged ALP expression and bone mineral deposition following treatment, pointing to osteoclastogenesis inhibition as the primary mechanism by which PRMT6 inhibition preserves bone integrity in OVX‐induced osteoporosis.